Abstract:Lisda Amalia Department of Neurology, The First Affiliated Hospital of Faculty of Medicine, Universitas Padjadjaran/RSUP dr. Hasan Sadikin, Bandung, Indonesia Correspondence: Lisda Amalia Jl.Pasteur 38, Bandung, 40161, Indonesia Email Introduction: Blockage of the cerebral arteries due to thrombosis and embolism resulting in decreased blood flow to the brain, reduced oxygen supply to the brain, resulting in neuronal damage and causes astrocyte cells to secrete glial fibrillary acidic protein (GFAP). The objective of this study was to determine the correlation between GFAP levels serum and clinical outcome in patients with acute ischemic stroke. Methods: This was observational with a cross-sectional design on acute ischemic stroke patients confirmed by CT scans and divided into large vessel occlusion and small-vessel occlusion. Clinical outcome was measured using the National Institutional Health Stroke Scale (NIHSS) tool. Statistical analysis uses Spearman's rank correlation test and Mann Whitney's test, significant if p < 0.05. Results: After collecting 33 research subjects, we found 16 people with large vessel occlusion and 17 people with small vessel occlusion. Serum GFAP levels were 0.2– 1.9 ng/mL, 9.1% with a mild neurological deficit, 45.45% were moderate neurological deficits, and 45.45% were severe neurological deficits. There was a significant positive correlation (r = 0.522; p = 0.002) between serum GFAP levels and the degree of neurological deficit in ischemic stroke patients. There was a statistically significant difference between serum GFAP levels in ischemic stroke patients with CT scan results of large artery occlusion compared to small artery occlusion (0.7 vs 0.4ng/mL; p = 0.001). Conclusion: There was a positive correlation between GFAP level serum and NIHSS score on acute ischemic stroke. The higher the value of GFAP serum level, the higher the value for NIHSS and correlated with stroke severity and the extent of brain damage in ischemic stroke patients. Keywords: GFAP, clinical outcome, acute ischemic stroke, small vessel occlusion, large vessel occlusion Stroke is a neurological emergency that arises suddenly and is the 3rd cause of death in the world after heart disease and cancer. 1 Ischemic stroke is the most common type of stroke, accounting for 87% of all strokes worldwide. Impaired blood-brain barrier permeability causes GFAP to diffuse into the cerebrospinal fluid and then enter the blood circulation to detect GFAP levels in the blood. GFAP levels can begin to be detected in the blood after 12 hours of the onset of ischemic stroke and reach the highest levels after 48 hours of the onset of ischemic stroke. 2,3 There is hyperreactivity of astrocytes as a result of glutamate excitotoxicity, which can cause changes in astrocytes, namely astrocytes experience hypertrophy and proliferation which is referred to as the astrogliosis process in acute ischemic stroke. Prolonged astrogliosis in patients with brain ischemia can increase neuronal death and exacerbate brain tissue degeneration. This astrogliosis process is characterized by a rapid and high increase in GFAP levels because damaged astrocytes secrete GFAP. Astrocytes are cells that make up the blood-brain barrier, so if there is damage to the blood-brain barrier, it will cause GFAP levels to increase and enter the bloodstream. 4 GFAP level serum can be used to assess neurologic deficits, monitor therapy, and prognosticate ischemic stroke. In ischemic stroke, the greater the damage to neurons and neuroglia, the serum GFAP levels will increase, and there is a relationship between high GFAP levels and the severity of the neurological deficit and the extent of brain damage in ischemic stroke patients. The larger the infarct area, the higher the serum GFAP level and NIHSS score. 3 Based on the above framework, this study aims to determine the correlation between serum GFAP levels and clinical outcomes based on the NIHSS score in ischemic stroke patients. It was an observational correlative analysis with a cross-sectional design at RSUP. Dr. Hasan Sadikin from June 2015 to November 2015. The research subjects were patients diagnosed with ischemic stroke confirmed by CT scan who came to the hospital within five days after stroke onset and were grouped into large vessel occlusion and small-vessel occlusion based on clinical symptoms and imaging. We exclude the presence of a history of previous stroke, head trauma, patients with glioblastoma multiforme. The results of the NIHSS criteria assessment are scores, namely a score of 12 indicating a severe neurological deficit. Examination -Abstract Truncated-

The relationship between the serum glial fibrillary acidic protein level and cognitive function of first-epi-sode depression patients

Clinical significance of serum glial fibrillary acidic protein level in middle-aged and elderly patients with Parkinson's disease

Correlation of neurochemical metabolism with memory function in young adult patients with first-episode depression studied with proton magnetic resonance spectroscopy]

The Association Between Plasma Neurotransmitters Levels and Depression in Acute Hemorrhagic Stroke

Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression

Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke

Relationship between serum levels of BDNF,IL-6 and Hcy with cognitive function impairment in patients with first episode schizophrenia

Depressive Symptoms, Glial Fibrillary Acid Protein Concentrations, and Cognitive Decline in a Cohort Study

Study on changes of the levels of EGF, BDNF in serum and their relations with cognitive impairment in patients with Parkinson's disease

Dynamic Changes of Serum Glial Fibrillary Acidic Protein Content in Patients with Brain Injury and Their Cllnical Significance

Dynamic changes and its clinical significance of serum glial fibrillary acidic protein content in patients with acute cerebral infarction

Serum NCAM Levels and Cognitive Deficits in First Episode Schizophrenia Patients Versus Health Controls

Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort

Characteristics of regional cerebral metabolic rate of glucose in association with the neuropsychological changes after the treatment of first-episode depression

The protein and mRNA expression levels of glial cell line-derived neurotrophic factor in post stroke depression and major depressive disorder

Cognitive Impairment in First-Episode Drug-Naïve Patients with Schizophrenia: Relationships with Serum Concentrations of Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor.

Decreased Serum EGF in First-episode and Chronic Schizophrenia Patients: Negative Correlation with Psychopathology

A population‐based meta‐analysis of circulating GFAP for cognition and dementia risk

The study on the relationship of cognitive function and the frontal gray matter concentration in female major depression.

Plasma GFAP in Parkinson’s Disease with Cognitive Impairment and Its Potential to Predict Conversion to Dementia

Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke